Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) Project
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Solid Tumor. Basic parameters: from 12 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Singapore
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study aims to screen tumor molecular profile for better selection of anticancer treatment, in particular, allocation to clinical trials if available.
Detailed description
Molecular profiling will be performed on archival tumor tissue or freshly collected tumor tissue from re-biopsy. Blood, pleural fluid, FNA, and/or saliva may be collected to study the genetic makeup and also to compare the tumor molecular profile. Personalized therapy will be given based on molecular profile.
Primary outcome measures
- The molecular and clinical epidemiology for cancer patients being considered for novel therapeutics [Time frame: 5 years]
Secondary outcome measures (2)
- The proportion of patients who have actionable alterations and enrol into clinical trials [Time frame: 5 years]
- The correlation of molecular profiles with clinical outcomes [Time frame: 5 years]
Eligibility criteria
Inclusion criteria
- Confirmed histological diagnosis of solid tumor
- Suitable for systematic treatment and clinical trials
- ECOG (Eastern cooperative oncology group) performance status < 2
- Able to provide tumor tissue for molecular profiling
- Able to understand and sign the informed consent form
Exclusion criteria
- None
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Singapore · 1 center
- National Cancer Centre, Singapore — Singapore
Publications
- Chia S, Low JL, Zhang X, Kwang XL, Chong FT, Sharma A, Bertrand D, Toh SY, Leong HS, Thangavelu MT, Hwang JSG, Lim KH, Skanthakumar T, Tan HK, Su Y, Hui Choo S, Hentze H, Tan IBH, Lezhava A, Tan P, Tan DSW, Periyasamy G, Koh JLY, Gopalakrishna Iyer N, DasGupta R. Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nat Commun. 2017 Sep 5;8(1):435. doi: 10.10 PMID 28874669
Identifiers
NCT: NCT02806388 · ECRU-IMPACT